Halozyme Therapeutics (HALO) shares were down about 4.7% in recent Wednesday trading after Morgan Stanley downgraded the company's stock to equalweight from overweight and cut its price target to $62 from $73.
Trading volume stood at nearly 4.4 million shares against a daily average of about 2 million.
Price: 47.90, Change: -2.33, Percent Change: -4.65